Navigation Links
Panmira and FLAP LLCs Spun Out of Amira Pharmaceuticals
Date:9/8/2011

SAN DIEGO, Sept. 8, 2011 /PRNewswire/ -- Panmira Pharmaceuticals, LLC and FLAP, LLC, today announced their formation around certain assets spun out immediately preceding the acquisition of Amira Pharmaceuticals, Inc. (Amira) by Bristol-Myers Squibb Company (NYSE: BMY).  Panmira Pharmaceuticals received a number of assets, including Amira's DP2 antagonists, AM211 and AM461, both of which have successfully completed Phase I clinical studies.  FLAP, LLC is a non-operating company with rights to future milestones and royalties from Amira's 2008 licensing deal with GlaxoSmithKline related to the 5-lipoxygenase-activating protein (FLAP) inhibitor program.

"Now that we have successfully completed the sale of Amira to Bristol-Myers Squibb Company, a subset of the former Amira team will focus on completing our partnership efforts for the DP2 program," said Bob Baltera, Chief Executive Officer of Panmira Pharmaceuticals.  "We believe that spinning out these assets will be the best way to maximize their value for Amira's shareholders, and we look forward to accomplishing this goal."

Hari Kumar, Ph.D., Chief Business Officer, added, "Clinical trial results have demonstrated a dose proportional pharmacodynamic (PD) effect and good safety profiles for both AM211 and AM461.  These compounds are primed and ready for Phase II exploration in a number of clinical settings, including asthma, chronic obstructive pulmonary disease (COPD) and eosinophillic esophagitis.  We look forward to having the right partner to help make these plans come to fruition."

While there are no DP2 selective antagonists approved for therapeutic use, there is a strong scientific rationale for the target to be a novel, potentially disease-modifying treatment of asthma, COPD and allergic rhinitis. DP2, also known as chemoattractant receptor-homologous molecule expressed in Th2 lymphocytes (CRTH2), is a high affinity receptor for the prostaglandin D2 and is implicated in humans in Th2-dependent allergic inflammation.

About Panmira

Founded in 2011 and headquartered in San Diego, Panmira Pharmaceuticals, LLC is a small molecule pharmaceutical company focused on partnering clinical candidates for inflammatory diseases.  Panmira was spun out of Amira Pharmaceuticals prior to Amira's acquisition by Bristol-Myers Squibb. For more information, visit www.panmira.com.


'/>"/>
SOURCE Panmira Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amira Pharmaceuticals to Present Preclinical Data on AM152 , an LPA1 Receptor Antagonist, at the Annual Meeting of the American Thoracic Society
2. Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
3. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
4. Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor
5. Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist
6. Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
7. Amira Pharmaceuticals Named One of Most Promising Biotech Companies by FierceBiotechs Annual Fierce 15
8. Visage Imaging Releases Amira 5.3
9. Amira Announces AM103 and AM803 Patent Grant in the United Kingdom
10. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
11. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... 2016 - DCGI grants limited approval to ... disease - Stempeucel® becomes 5th off-the-shelf Stem cell product ... - Buerger,s Disease (also known as Thromboangiitis Obliterans) is ... and Globally - Prevalence of Buerger,s Disease is estimated ... per 10,000 persons in the European Community & USA ...
(Date:5/27/2016)... study highlights the necessity of health literacy within the technology advancement of diagnostic imaging. According ... , a majority of oncology patients undergo imaging screenings without understanding the nuanced risks ... ... ... Medical Diagnostic Imaging Ampronix ...
(Date:5/27/2016)... , May 27, 2016 ... innovative biopharma company focused on the highly lucrative ... a substantial pipeline of potential first-in-class or best-in-class ... are in development with strategic partners. HCM,s profitable ... fast-growing domestic market. We expect progress of the ...
Breaking Medicine Technology:
(Date:5/29/2016)... ... , ... "With 30 unique self-animating web themed intros and complete control over ... said Christina Austin - CEO of Pixel Film Studios. , ProIntro Web Volume ... Final Cut Pro X. Pixel Film Studios’ minimalistic titles allow users to add a ...
(Date:5/28/2016)... ... May 28, 2016 , ... "Color Grading media can be time ... preset onto their media," said Christina Austin - CEO of Pixel Film Studios. ... and easily add stylish color grades to their footage. A LUT is a Lookup ...
(Date:5/28/2016)... ... May 28, 2016 , ... After a year and a half of planning the Multiple ... The Multiple Pathways of Recovery Conference was held May 2 -4, 2016 at the ... United Kingdom came together to explore the many pathways individuals use to get into and ...
(Date:5/27/2016)... ... 2016 , ... More than a third of American adults are considered obese, ... has received increased attention in recent years, as an article published May ... loss, most people are familiar with the basic requirements of maintaining a healthy diet ...
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of Horizon ... to Women and Industry (TWIN) 2016 honorees. The award recognizes businesswomen who excel ... year, Geri Boone, Director of the MLTSS (Managed Long-Term Services and Supports) Program at ...
Breaking Medicine News(10 mins):